Abstract
Frequent use of Type 2 Diabetes Mellitus (T2DM) drugs brings substantial economic burden to patients which could be eased by their successful listing into the National Reimbursement Drug List (NRDL) in China. Pharmacoeconomic evidence becomes increasingly important in reimbursement decision-making, with quality-adjusted life-year (QALY) being a critical indicator of health outcomes. This study aims to review published local economic evaluations (EEs) of negotiated T2DM drugs in 2020 NRDL and evaluate the range of QALY gains.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
